Fig. 5.

Muscle lipid metabolite accumulation and levels of tricarboxylic acid cycle intermediates in HFD-induced obese mice after 22 days of treatment with trimetazidine. (A) Gastrocnemius triacylglycerol content. (B) Long-chain acyl-CoA content. (C) Diacylglycerol content. (D) Ceramide content. (E) Tricarboxylic acid (TCA) cycle intermediate levels. Medium-chain acylcarnitine content (F) and long-chain acylcarnitine content (G) in saline and trimetazidine-treated HFD-induced obese mice. (H–I) Plasma long-chain acylcarnitine content in saline and trimetazidine-treated HFD-induced insulin-resistant mice. Values represent mean ± S.E. (n = 6). Differences were determined by the use of an unpaired, two-tailed Student’s t test. *P < 0.05, significantly different from HFD-induced insulin-resistant saline-treated mice.